Elisabetta Bugianesi

Summary

Country: Italy

Publications

  1. ncbi Insulin resistance: a metabolic pathway to chronic liver disease
    Elisabetta Bugianesi
    Gastroenterology Department, University of Turin, Turin, Italy
    Hepatology 42:987-1000. 2005
  2. doi Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes
    Anna Ludovica Fracanzani
    Department of Internal Medicine, Scientific Institute of Recovery and Cure Foundation IRCCS, Hospital Maggiore Policlinico, University of Milan, Milan, Italy
    Hepatology 48:792-8. 2008
  3. ncbi Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
    Elisabetta Bugianesi
    Department of Gastroenterology, Ospedale S Giovanni Battista, University of Turin, Turin, Italy
    Gastroenterology 123:134-40. 2002
  4. ncbi A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
    Elisabetta Bugianesi
    Department of Gastroenterology, University of Turin, Italy
    Am J Gastroenterol 100:1082-90. 2005
  5. doi Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C
    Ester Vanni
    Division of Gastro Hepatology, San Giovanni Battista Hospital, University of Turin, Turin, Italy
    Hepatology 50:697-706. 2009
  6. doi Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study
    Chiara Giordanino
    Division of Gastroenterology, University of Turin, San Luigi Medical School, Orbassano, Italy
    Dig Liver Dis 44:406-12. 2012
  7. ncbi NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes
    Elisabetta Bugianesi
    Division of Gastro Hepatology, University of Turin, S Giovanni Battista Hospital, Corso Bramante 88, Turin 10126, Italy
    Curr Diab Rep 7:175-80. 2007
  8. pmc Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014
    Giorgio Maria Saracco
    Giorgio Maria Saracco, Department of Oncology, University of Turin, 10123 Turin, Italy
    World J Gastroenterol 22:8187-93. 2016
  9. doi Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis
    Chiara Rosso
    Liver Physiopathology Lab, Department of Medical Sciences, University of Turin, Turin, Italy Electronic address
    Dig Liver Dis 48:55-61. 2016
  10. doi Hepatic and cardiac steatosis: are they coupled?
    Elisabetta Bugianesi
    Division of Gastro Hepatology, Department of Internal Medicine, San Giovanni Battista Hospital, University of Turin, Corso Dogliotti 14, Turin, Italy
    Heart Fail Clin 8:663-70. 2012

Collaborators

Detail Information

Publications36

  1. ncbi Insulin resistance: a metabolic pathway to chronic liver disease
    Elisabetta Bugianesi
    Gastroenterology Department, University of Turin, Turin, Italy
    Hepatology 42:987-1000. 2005
    ..Finally, the ability of insulin-sensitizing, pharmacological agents to treat NAFLD by reducing IR in the liver (metformin) and in the periphery (thiazolidinediones) are discussed...
  2. doi Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes
    Anna Ludovica Fracanzani
    Department of Internal Medicine, Scientific Institute of Recovery and Cure Foundation IRCCS, Hospital Maggiore Policlinico, University of Milan, Milan, Italy
    Hepatology 48:792-8. 2008
    ..07; 95% CI, 1.02-1.14), and diabetes (OR, 1.8; 95% CI, 1.4-2.3) in the overall series, serum ferritin and diabetes in those with increased ALT, and only HOMA-IR (OR, 1.97; 95% CI, 1.2-3.7) in patients with normal ALT...
  3. ncbi Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
    Elisabetta Bugianesi
    Department of Gastroenterology, Ospedale S Giovanni Battista, University of Turin, Turin, Italy
    Gastroenterology 123:134-40. 2002
    ..Nonalcoholic steatohepatitis (NASH) may progress to cirrhosis; whether NASH plays also a role in the development of hepatocellular carcinoma (HCC) is unknown...
  4. ncbi A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
    Elisabetta Bugianesi
    Department of Gastroenterology, University of Turin, Italy
    Am J Gastroenterol 100:1082-90. 2005
    ..We aimed to compare the usefulness of metformin versus prescriptive diet or vitamin E...
  5. doi Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C
    Ester Vanni
    Division of Gastro Hepatology, San Giovanni Battista Hospital, University of Turin, Turin, Italy
    Hepatology 50:697-706. 2009
    ..The decreased insulin-stimulated suppression of EGP was associated with increased hepatic suppressor of cytokine signaling 3 (SOCS3; P < 0.05) and interleukin-18 (P < 0.05) expression...
  6. doi Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study
    Chiara Giordanino
    Division of Gastroenterology, University of Turin, San Luigi Medical School, Orbassano, Italy
    Dig Liver Dis 44:406-12. 2012
    ....
  7. ncbi NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes
    Elisabetta Bugianesi
    Division of Gastro Hepatology, University of Turin, S Giovanni Battista Hospital, Corso Bramante 88, Turin 10126, Italy
    Curr Diab Rep 7:175-80. 2007
    ..Although cardiovascular risk remains the major cause for excess mortality in type 2 diabetes mellitus, the risk of progressive liver disease should no longer be underscored...
  8. pmc Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014
    Giorgio Maria Saracco
    Giorgio Maria Saracco, Department of Oncology, University of Turin, 10123 Turin, Italy
    World J Gastroenterol 22:8187-93. 2016
    ..To assess the etiology of chronic liver diseases (CLD) from 1998 to 2014 at the outpatient clinic of Gastroenterology of the main hospital in Northwest of Italy among those dedicated to hepatology...
  9. doi Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis
    Chiara Rosso
    Liver Physiopathology Lab, Department of Medical Sciences, University of Turin, Turin, Italy Electronic address
    Dig Liver Dis 48:55-61. 2016
    ..The combination of non-invasive markers for the detection of fibrosis in patients with chronic liver diseases is still a matter of debate...
  10. doi Hepatic and cardiac steatosis: are they coupled?
    Elisabetta Bugianesi
    Division of Gastro Hepatology, Department of Internal Medicine, San Giovanni Battista Hospital, University of Turin, Corso Dogliotti 14, Turin, Italy
    Heart Fail Clin 8:663-70. 2012
    ..Collectively these findings suggest the presence of complex and intertwined interrelationships between NAFLD, myocardial steatosis, and coronary artery disease...
  11. pmc Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C
    Gianluca Svegliati-Baroni
    Department of Gastroenterology, Polytechnic University of Marche, Ancona, Italy
    Gut 60:108-15. 2011
    ..To study the mechanism(s) linking insulin resistance (IR) to hepatic fibrosis and the role of the epithelial component in tissue repair and fibrosis in chronic hepatitis C (CHC)...
  12. ncbi Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis
    Elisabetta Bugianesi
    Gastroenterology Department, University of Turin, Italy
    Hepatology 44:1648-55. 2006
    ..Virus-induced hepatic steatosis as seen in CHC-3 does not contribute significantly to liver fibrosis...
  13. doi Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study
    Chiara Giordanino
    Gastroenterology, Molinette Hospital, Turin, Italy
    Am J Gastroenterol 103:2481-7. 2008
    ..Patients with chronic hepatitis C are at risk of developing type 2 diabetes mellitus (DM) and impaired fasting glucose (IFG), and this risk may increase among hepatitis C virus (HCV) patients not responding to an antiviral therapy...
  14. pmc Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load
    Roberto Gambino
    Department of Medical Sciences, University of Turin, C so Dogliotti 14, 10126 Torino, Italy
    Int J Mol Sci 17:479. 2016
    ..This work studied the increase in total FFA shown in NAFLD subjects to possibly characterize which fatty acids significantly accounted for the whole increase...
  15. doi The interaction of metabolic factors with HCV infection: does it matter?
    Elisabetta Bugianesi
    Department of Internal Medicine, University of Turin, Italy
    J Hepatol 56:S56-65. 2012
    ..Thus, targeted lifestyle and pharmacological measures are urgently warranted in chronic hepatitis C with metabolic alterations...
  16. doi Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C: Results of a retrospective long-term controlled cohort study
    Claudia Coppo
    Gastroenterology Unit, Department of Oncology, University of Turin, Turin, Italy
    Dig Liver Dis 47:405-10. 2015
    ..Patients with chronic hepatitis C have an increased risk of diabetes mellitus but the type and risk of developing diabetes-related complications have not yet been evaluated...
  17. ncbi Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity
    Elisabetta Bugianesi
    Division of Gastroenterology, University of Turin, Ospedale San Giovanni Battista, Corso Bramante 88, I 10126 Torino, Italy
    J Clin Endocrinol Metab 90:3498-504. 2005
    ..Hypoadiponectinemia in NAFLD is part of a metabolic disturbance characterized by ectopic fat accumulation in the central compartment...
  18. doi From the metabolic syndrome to NAFLD or vice versa?
    Ester Vanni
    Division of Gastro Hepatology, San Giovanni Battista Hospital, University of Turin, c so Bramante 88, 10126 Turin, Italy
    Dig Liver Dis 42:320-30. 2010
    ..Recently nuclear receptors have emerged as key regulators of lipid and carbohydrate metabolism for which specific pharmacological ligands are available, making them attractive therapeutic targets for NAFLD and NASH...
  19. ncbi Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver
    Elisabetta Bugianesi
    Division of Gastro Hepatology, Department of Internal Medicine, University of Turin, Turin, Italy
    Hepatology 39:179-87. 2004
    ..Increased ferritin levels are markers of severe histologic damage, but not of iron overload. Iron burden and HFE mutations do not contribute significantly to hepatic fibrosis in the majority of patients with NAFLD...
  20. doi Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease
    Chiara Rosso
    Division of Gastroenterology and Hepatology and Laboratory of Diabetology, Department of Medical Sciences, University of Turin, Turin, Italy
    Hepatology 63:107-16. 2016
    ..57, 95% confidence interval 0.45-0.72, P < 0.001) and was also able to discriminate F2 from F3/F4 (P < 0.003)...
  21. doi Non-invasive score system for fibrosis in chronic hepatitis: proposal for a model based on biochemical, FibroScan and ultrasound data
    Silvia Gaia
    Department of Gastroenterology, Città della Salute e della Scienza University Hospital, Turin, Italy
    Liver Int 35:2027-35. 2015
    ..We elaborate a non-invasive score system for liver fibrosis (NISF), exploring its diagnostic performance and comparing its accuracy to FibroScan in patients with chronic viral hepatitis (CH) and non-alcoholic fatty liver disease (NAFLD)...
  22. doi Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
    Andrea Marengo
    Division of Gastroenterology and Hepatology, Department of Medical Sciences, A O Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy Email
    Annu Rev Med 67:103-17. 2016
    ..This review summarizes current evidence linking obesity, NAFLD and liver cancer, discusses its clinical impact and describes the main mechanisms underlying this complex relationship. ..
  23. ncbi Is liver disease a threat to patients with metabolic disorders?
    Giulio Marchesini
    Unit of Metabolic Diseases, Alma Mater Studiorum University, Bologna, and San Giovanni Battista Hospital, Turin, Italy
    Ann Med 37:333-46. 2005
    ....
  24. ncbi Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
    Elisabetta Bugianesi
    Department of Gastroenterology, San Giovanni Battista Hospital, University of Turin, Corso Bramante 88, I 10127 Turin, Italy
    Best Pract Res Clin Gastroenterol 18:1105-16. 2004
    ..Large, long-term, placebo-controlled randomized studies are eagerly awaited. Outside controlled studies, nutritional counselling and physical exercise aimed at moderate weight loss remain the basis of any therapeutic intervention...
  25. doi Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults
    Andrea Marengo
    Division of Gastroenterology and Hepatology, Department of Medical Sciences, A O Città della Salute e della Scienza di Torino, University of Turin, Corso Bramante 88, Turin I 10126, Italy
    Clin Liver Dis 20:313-24. 2016
    ..Progression of liver disease is observed in up to one-third of patients with NASH. The long-term hepatic prognosis mostly depends on the histologic stage at initial liver biopsy, but multiple risk factors may concur. ..
  26. pmc Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers
    Claudia Sanna
    Division of Gastroenterology, Department of Medical Sciences, A O Città della Salute e della Scienza di Torino, University of Turin, 10126 Turin, Italy
    Int J Mol Sci 17:. 2016
    ..In this review we critically appraise key studies on NAFLD-associated extra-hepatic cancers and speculate on how NAFLD may influence carcinogenesis at these sites. ..
  27. doi Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?
    Ester Vanni
    Gastro Hepatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy
    Dig Liver Dis 48:105-11. 2016
    ..The scope of this review is to summarise the current evidence linking successful antiviral treatment and the prevention of type 2 diabetes mellitus and its complications in hepatitis C-infected patients. ..
  28. doi Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
    Ester Vanni
    Department of Medical Sciences, Division of Gastro Hepatology, A O Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
    Semin Liver Dis 35:236-49. 2015
    ....
  29. pmc The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease
    Luca Miele
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Gastroenterology 135:282-291.e1. 2008
    ..Based on its role in liver growth and repair, we explored whether Kruppel-like factor 6 (KLF6) plays a role in NAFLD progression...
  30. ncbi Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study
    Luca Valenti
    Department of Internal Medicine, Universita di Milano, Ospedale Policlinico Mangiagalli Regina Elena IRCCS, Milano, Italy
    Am J Gastroenterol 102:1251-8. 2007
    ..Aims of this study were to define the relationship between ferritin and iron stores in patients with NAFLD, the effect of iron depletion on insulin resistance, and whether basal ferritin levels influence treatment outcome...
  31. ncbi Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
    Giulio Marchesini
    Unit of Metabolic Diseases and Department of Internal Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy
    Hepatology 37:917-23. 2003
    ..The increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades...
  32. ncbi Nonalcoholic fatty liver disease and the metabolic syndrome
    Giulio Marchesini
    Unit of Metabolic Diseases, Alma Mater Studiorum University of Bologna, Italy
    Curr Opin Lipidol 16:421-7. 2005
    ..Insulin resistance is the common factor connecting obesity, diabetes, hypertension and dyslipidemia with fatty liver and the progression of hepatic disease to steatohepatitis, fibrosis, cirrhosis and hepatocellular carcinoma...
  33. ncbi Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children
    Valerio Nobili
    Liver Unit, Research Institute, Bambino Gesu Children s Hospital, Piazza S Onofrio 4, 00165 Rome, Italy
    Diabetes Care 30:2638-40. 2007
  34. ncbi Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease
    Nicola Villanova
    Unit of Metabolic Diseases, Alma Mater Studiorum University of Bologna, Policlinico S Orsola Malpighi, Via Massarenti 9, I 40138 Bologna, Italy
    Hepatology 42:473-80. 2005
    ..The risk of advanced liver disease is well recognized in NAFLD patients, but the large majority of cases might experience cardiovascular disease in the long term, indirectly limiting the burden of liver failure...
  35. ncbi Non-alcoholic steatohepatitis in patients cared in metabolic units
    Giulio Marchesini
    Unit of Metabolic Diseases, Department of Internal Medicine and Gastroenterology, University of Bologna, Alma Mater Studiorum, Via Massarenti 9, Policlinico S Orsola, I 40138 Bologna, Italy
    Diabetes Res Clin Pract 63:143-51. 2004
    ..Liver biopsy is recommended for diagnostic and prognostic purposes, as well as for testing treatment effects in controlled trials...
  36. ncbi Nonalcoholic fatty liver disease (NAFLD) and cardiac lipotoxicity: Another piece of the puzzle
    Elisabetta Bugianesi
    Hepatology 47:2-4. 2008